Keryx Biopharmaceuticals (NASDAQ:KERX) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, MarketWatch Earnings reports. The business had revenue of $28.04 million during the quarter, compared to the consensus estimate of $29.56 million.

NASDAQ KERX traded up $0.21 on Friday, hitting $3.24. The stock had a trading volume of 3,342,206 shares, compared to its average volume of 879,466. Keryx Biopharmaceuticals has a 52-week low of $2.74 and a 52-week high of $5.98. The firm has a market capitalization of $359.92 million, a P/E ratio of -3.68 and a beta of 2.46.

An institutional investor recently raised its position in Keryx Biopharmaceuticals stock. Bank of New York Mellon Corp grew its position in Keryx Biopharmaceuticals (NASDAQ:KERX) by 10.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,056,811 shares of the biopharmaceutical company’s stock after purchasing an additional 102,014 shares during the quarter. Bank of New York Mellon Corp owned about 0.88% of Keryx Biopharmaceuticals worth $3,974,000 at the end of the most recent reporting period. 59.41% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on KERX shares. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 28th. BidaskClub downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 13th. HC Wainwright set a $9.00 price objective on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 23rd. Finally, Citigroup reduced their price objective on shares of Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, August 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $6.25.

TRADEMARK VIOLATION NOTICE: “Keryx Biopharmaceuticals (KERX) Announces Earnings Results, Beats Estimates By $0.01 EPS” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://theolympiareport.com/2018/11/10/keryx-biopharmaceuticals-kerx-announces-earnings-results-beats-estimates-by-0-01-eps.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Read More: Are Wall Street analysts’ stock ratings worth following?

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.